Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
2021 · Journal of Clinical Oncology · 947 citations
https://doi.org/10.1200/jco.20.03399
E
E. Shelley Hwang
Duke University(US)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
163
Papers
5.5K
Citations
34
h-index
75
i10-index
E. Shelley Hwang is an academic researcher from Duke University. The author has contributed to research in topics: Breast Cancer Treatment Studies & Breast Lesions and Carcinomas & Breast Implant and Reconstruction. The author has an h-index of 34, co-authored 139 publications.
Papers by this author
worksDuctal carcinoma in situ: to treat or not to treat, that is the question
2019 · British Journal of Cancer · 329 citations
https://doi.org/10.1038/s41416-019-0478-6
Elective Cancer Surgery in COVID-19–Free Surgical Pathways During the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study
2020 · Journal of Clinical Oncology · 222 citations
https://doi.org/10.1200/jco.20.01933
Association of Low Nodal Positivity Rate Among Patients With <i>ERBB2</i>-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy
2018 · JAMA Surgery · 147 citations
https://doi.org/10.1001/jamasurg.2018.2696
Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer
2012 · Breast Cancer Research and Treatment · 115 citations
https://doi.org/10.1007/s10549-012-2233-z
Machine learning risk prediction of mortality for patients undergoing surgery with perioperative SARS-CoV-2: the COVIDSurg mortality score
2021 · British journal of surgery · 46 citations
https://doi.org/10.1093/bjs/znab183
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat